EUVIMEDEUVIMED entdecken
LeitlinieOpen Access · CC BY-NC 4.0

Successful Amendment of an Existing Hepatitis B Screening Programme by a Guideline Recommended Hepatitis D Screening in the Primary Care Setting

Toni Herta iD, Anna Joachim-Richter, David Petroff iD, Benno Wölk, Ingmar Wolffram, Thomas Berg, Jan Kramer, Olaf Bätz, Johannes Wiegand iD

Alimentary Pharmacology & Therapeutics · 2025-02 · 61 (4) · 651-657

DOI: 10.1111/apt.18424 ↗

Kurz gefasst

Leitlinie in der Zeitschrift Alimentary Pharmacology & Therapeutics, online erschienen am 04.12.2024. Verfasst von Toni Herta und 8 weiteren Autor:innen. Beteiligte Einrichtung: Division of Hepatology, Department of Medicine II, Leipzig University Medical Center, Leipzig, Germany. Hauptthemen laut MEDLINE: Mass Screening, Hepatitis D, Hepatitis B. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Gilead Sciences.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Despite European guidelines recommending anti‐hepatitis D virus (HDV) screening for all hepatitis B surface antigen (HBsAg)‐positive cases, screening rates remain insufficient.

Aims

We analysed anti‐HDV screening rates in primary care and implemented prospective HDV screening in HBsAg‐positive cases identified in the preventive medical examination from the age of 35 (“Check‐Up 35+”).

Methods

From 2012 to 2021, we reviewed anti‐HDV and HDV RNA test rates in HBsAg‐positive patients at 11 sites of a large German laboratory group. From 2022 to 2023, we prospectively screened HBsAg‐positive samples from the “Check‐Up 35+” for anti‐HDV. Anti‐HDV positive patients were then contacted again for HDV RNA testing.

Results

Retrospectively, 2792/13,905 (20%) HBsAg‐positive cases were tested for anti‐HDV, with 142/2792 (5.1%) being positive. HDV RNA was tested in 57/142 (40%) anti‐HDV‐positive cases, with 26/57 (46%) being positive. In the prospective screening, 1159/225,901 (0.51%) individuals were HBsAg‐positive. Of these, 700 (60%) were tested for anti‐HDV, with 18/700 (2.6%) positive test results. 4/18 (22%) were successfully contacted again for HDV RNA analysis, with one case testing positive. Neither the HBsAg nor the anti‐HDV positive result was known prior to screening in these cases. Anti‐HDV testing could not be performed in 459/1159 (40%) HBsAg‐positive cases, primarily due to insufficient blood sample volume (310/459 cases, 68%), with others missed due to logistical errors.

Conclusions

Retrospective data show insufficient anti‐HDV screening in clinical routine. The prospective anti‐HDV screening provides a blueprint for using existing hepatitis B virus screening programms for population‐based HDV double reflex testing, provided that adequate logistical prerequisites are established. Trial Registration German Clinical Trial Register: DRKS00029180

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Mass ScreeningHepatitis DHepatitis BHumansPrimary Health CareAdultMaleFemaleHepatitis B Surface AntigensProspective StudiesRetrospective StudiesPractice Guidelines as TopicMiddle AgedHepatitis Delta VirusGermanyRNA, Viral

Stichwörter der Autor:innen

HDV prevalenceHDV reflex testingHDV screeningcheck‐up 35+primary care

Substanzen

Hepatitis B Surface AntigensRNA, Viral

Autor:innen und Institutionen

  • Division of Hepatology, Department of Medicine II, Leipzig University Medical Center, Leipzig, Germany.
  • Department of Hepatology and Gastroenterology, Campus Virchow-Klinikum and Campus Charité Mitte, Charité-Universitätsmedizin Berlin, Berlin, Germany.
  • Berlin Institute of Health at Charité-Universitätsmedizin Berlin, BIH Biomedical Innovation Academy, BIH Charité Clinician Scientist Program, Berlin, Germany.
  • LADR Laboratory Group Dr. Kramer & Colleagues, Geesthacht, Germany.
  • Clinical Trial Centre Leipzig, University of Leipzig, Leipzig, Germany.
  • General Practitioner, Paderborn, Germany.

ORCID-Profile: Toni Herta, David Petroff, Johannes Wiegand

Förderung

  • Gilead Sciences

Zitieren

APA

Herta, T., Joachim-Richter, A., Petroff, D., Wölk, B., Wolffram, I., Berg, T., Kramer, J., Bätz, O., & Wiegand, J. (2025). Successful Amendment of an Existing Hepatitis B Screening Programme by a Guideline Recommended Hepatitis D Screening in the Primary Care Setting. Alimentary Pharmacology & Therapeutics, 61(4), 651-657. https://doi.org/10.1111/apt.18424

Vancouver

Herta T, Joachim-Richter A, Petroff D, Wölk B, Wolffram I, Berg T, et al. Successful Amendment of an Existing Hepatitis B Screening Programme by a Guideline Recommended Hepatitis D Screening in the Primary Care Setting. Alimentary Pharmacology & Therapeutics. 2025;61(4):651-657. doi:10.1111/apt.18424

BibTeX
@article{Herta2025,
  author = {Herta, Toni and Joachim-Richter, Anna and Petroff, David and Wölk, Benno and Wolffram, Ingmar and Berg, Thomas and Kramer, Jan and Bätz, Olaf and Wiegand, Johannes},
  title = {Successful Amendment of an Existing Hepatitis B Screening Programme by a Guideline Recommended Hepatitis D Screening in the Primary Care Setting},
  journal = {Alimentary Pharmacology & Therapeutics},
  year = {2025},
  volume = {61},
  number = {4},
  pages = {651--657},
  doi = {10.1111/apt.18424}
}
Kostenlos starten →